WHP completes ADC Bio’s £5m cleanroom in UK site
WHP announced the completion of a cleanroom facility in Deeside, North Wales, UK, for ADC Bio, a biotechnology company developing anti-cancer, antibody drug conjugates (ADCs), under a £5m ($6.21m) contract.
The engineering company was awarded the contract to design, build, test and validate the current good manufacturing practice (cGMP) cleanroom within ADC Bio’s existing 6,500-square-meter facility, in December 2017.
The cleanroom adds to the company’s bioconjugation manufacturing plant, with support areas for washing, depyrogenation, thawing and buffer preparation, and it is expected to boost the company’s commercial production of anti-cancer drugs.
According to WHP, ADCs are “a class of emerging biotherapeutics that require a bespoke infrastructure to ensure strict compliance with the highest global regulatory standards.” The company suggested the facility will deliver “the next generation of anticancer blockbuster ADC drugs”.
The cleanroom includes complex zoned heating, ventilation, and air conditioning to maintain segregation, cleanliness, air pressures, and other environmental controls. It was developed in compliance with UK Medicines and Healthcare products Regulatory Agency’s regulations.
A key feature of the project, according to ADC, has been the installation of a bespoke low maintenance toxic waste system, which removes cleanroom waste to a holding tank, and transports it to an off-site incinerator, preventing the possibility of onsite contamination.
Chris Douglas, WHP’s project manager, said: “The new cleanroom meets ADC Bio’s need to expand operations at Deeside beyond R&D to include safe, secure and highly efficient manufacturing capabilities.”
